Overview | Analyst Coverage | Press Releases | Events & Presentations
Governance | SEC Filings | Annual Reports and Proxy Statement | Key Ratios
Stock Performance | Contact Us
Governance | SEC Filings | Annual Reports and Proxy Statement | Key Ratios
Stock Performance | Contact Us
Investor Relations
Corporate ProfileCatalyst Pharmaceutical Partners of Coral Gables, Florida, is a specialty pharmaceutical company focused on the development and commercialization of prescription drugs for the treatment of addiction. Catalyst has been granted an exclusive worldwide license from Brookhaven National Laboratory to nine U.S. patents and two U.S. patent applications relating to the use of vigabatrin for the treatment of a wide variety of substance abuses. Catalyst's product development efforts are currently focused on the development of vigabatrin (designated CPP-109 by Catalyst) as a treatment for cocaine and methamphetamine addiction. Annual Reports and Proxy Statement Recent Releases07/09/10European Patent Office Grants Patent for the Use of Vigabatrin/CPP-109 for the Prevention of Addiction to Opioids in Pain Management 06/09/10 Vigabatrin/CPP-109 Data to be Presented at College on Problems of Drug Dependence Annual Meeting Events06/16/10College on Problems of Drug Dependence - Methamphetamine Clinical Study Poster 06/15/10 College on Problems of Drug Dependence Presentation 6-15-10 |
Stock Information
Data delayed at least 20 min.
Shareholder Tools
|
||||||||
